Yet AR-negative breast cancers respond poorly to hormone therapy with reduced overall survival, while conversely AR-positive cancers are smaller with fewer lymph node metastases corresponding to a better prognosis, thus demonstrating the role of the AR as a biomarker [7]. The gene discussed is AR; the disease is breast cancer.